Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society May 21, 2019
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes Apr 9, 2019
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH Apr 1, 2019
Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019 Mar 11, 2019
